OBJECTIVES: To estimate the disease-specific survival of patients with complete removal of the seminal vesicles (SVs) at radical prostatectomy and to develop a nomogram for the prediction of SV invasion (SVI). METHODS: An analysis of 6740 patients from three institutions was performed. The primary outcome was biochemical failure analyzed according to the presence or absence of SVI using the Kaplan-Meier method and Cox proportional hazards model. The variables analyzed included age, biopsy Gleason score, clinical T stage, margin status, extracapsular extension, SVI, surgical Gleason score, initial prostate-specific antigen level, and institution. Logistic regression analysis was used to determine the preoperative factors predicting for SVI and create the model for the nomogram. RESULTS: Of the 6740 patients, 566 (8.4%) had positive SVs. The median follow-up was 33.4 months (range 1 to 239). The 5 and 10-year biochemical relapse-free survival rate was 38.0% and 25.6%, respectively, for patients with positive SVs and 85.7% and 77.2%, respectively, for patients with negative SVs (P <0.0001). In the multivariate model, all variables, except for biopsy Gleason score and T stage, were significant predictors of biochemical failure (P <0.05), and all variables, except for age, were predictors of SVI. The nomogram achieved an area under the curve of 0.80. CONCLUSIONS: These results have demonstrated that a substantial number of patients with SVI are disease free at 5 and 10 years after complete excision without adjuvant therapy. These findings suggest the therapeutic efficacy of complete SV excision and can identify those with a nomogram-predicted increased risk of SVI who might benefit from complete excision.
OBJECTIVES: To estimate the disease-specific survival of patients with complete removal of the seminal vesicles (SVs) at radical prostatectomy and to develop a nomogram for the prediction of SV invasion (SVI). METHODS: An analysis of 6740 patients from three institutions was performed. The primary outcome was biochemical failure analyzed according to the presence or absence of SVI using the Kaplan-Meier method and Cox proportional hazards model. The variables analyzed included age, biopsy Gleason score, clinical T stage, margin status, extracapsular extension, SVI, surgical Gleason score, initial prostate-specific antigen level, and institution. Logistic regression analysis was used to determine the preoperative factors predicting for SVI and create the model for the nomogram. RESULTS: Of the 6740 patients, 566 (8.4%) had positive SVs. The median follow-up was 33.4 months (range 1 to 239). The 5 and 10-year biochemical relapse-free survival rate was 38.0% and 25.6%, respectively, for patients with positive SVs and 85.7% and 77.2%, respectively, for patients with negative SVs (P <0.0001). In the multivariate model, all variables, except for biopsy Gleason score and T stage, were significant predictors of biochemical failure (P <0.05), and all variables, except for age, were predictors of SVI. The nomogram achieved an area under the curve of 0.80. CONCLUSIONS: These results have demonstrated that a substantial number of patients with SVI are disease free at 5 and 10 years after complete excision without adjuvant therapy. These findings suggest the therapeutic efficacy of complete SV excision and can identify those with a nomogram-predicted increased risk of SVI who might benefit from complete excision.
Authors: Giovanni Lughezzani; Alberto Briganti; Pierre I Karakiewicz; Michael W Kattan; Francesco Montorsi; Shahrokh F Shariat; Andrew J Vickers Journal: Eur Urol Date: 2010-08-06 Impact factor: 20.096
Authors: Shahrokh F Shariat; Michael W Kattan; Andrew J Vickers; Pierre I Karakiewicz; Peter T Scardino Journal: Future Oncol Date: 2009-12 Impact factor: 3.404
Authors: Fernando P Secin; Fernando J Bianco; Angel Cronin; James A Eastham; Peter T Scardino; Bertrand Guillonneau; Andrew J Vickers Journal: J Urol Date: 2008-12-13 Impact factor: 7.450
Authors: Michael Pinkawa; Marc D Piroth; Karin Fischedick; Richard Holy; Jens Klotz; Sandra Nussen; Barbara Krenkel; Michael J Eble Journal: Strahlenther Onkol Date: 2009-11-10 Impact factor: 3.621
Authors: M I Koukourakis; A Giatromanolaki; M Panteliadou; S E Pouliliou; P S Chondrou; S Mavropoulou; E Sivridis Journal: Br J Cancer Date: 2014-04-08 Impact factor: 7.640